Pharmerica (PMC) Misses Q3 EPS by 7c; Guides FY16 Below Views

Pharmerica (NYSE: PMC) reported Q3 EPS of $0.44, $0.07 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $512.6 million versus the consensus estimate of $530.01 million.

GUIDANCE:

Pharmerica sees FY2016 EPS of $1.84-$1.89, versus the consensus of $2.01. Pharmerica sees FY2016 revenue of $2.051-2.091 billion, versus the consensus of $2.13 billion.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• RCM Technologies (RCMT) Tops Q2 EPS by 17c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04